News Article

Multinational pharmaceutical and healthcare company Sanofi completed its acquisition of Blueprint Medicines Corporation on July 18, 2025, with Blueprint becoming an indirect, fully owned Sanofi subsidiary.  

This deal strengthens Sanofi’s rare disease and immunology portfolio, adding Ayvakit (the sole FDA-approved treatment for systemic mastocytosis) and early-stage assets like molecule inhibitor BLU-808. 

As of Friday, July 18, 2025, Blueprint common stock ceased to be traded on the NASDAQ Global Select Stock Market.